David O. Watson, the General Counsel of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently sold a portion of his holdings ...
Jeffrey Eisele, the Chief Development Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.8 billion market cap biopharmaceutical company, recently sold a portion of his holdings in the ...